Next‐generation genetic testing for retinitis pigmentosa

Kornelia Neveling(Radboud University Nijmegen), Rob W.J. Collin(Radboud University Nijmegen), Christian Gilissen(Radboud University Nijmegen), Ramon A. C. van Huet(Radboud University Nijmegen), Linda Visser(Rotterdam Eye Hospital), Michael Kwint(Radboud University Nijmegen), Sabine Gijsen(Radboud University Nijmegen), Marijke N. Zonneveld(Radboud University Nijmegen), Nienke Wieskamp(Radboud University Nijmegen), Joep de Ligt(Radboud University Nijmegen), Anna M. Siemiatkowska(Radboud University Nijmegen), Lies H. Hoefsloot(Radboud University Nijmegen), Michael F. Buckley(Radboud University Nijmegen), Ulrich Kellner(Helios Hospital Siegburg), Kari Branham(University of Michigan), Anneke I. den Hollander(Radboud University Nijmegen), Alexander Hoischen(Radboud University Nijmegen), Carel B. Hoyng(Radboud University Nijmegen), B. Jeroen Klevering(Radboud University Nijmegen), L. Ingeborgh van den Born(Rotterdam Eye Hospital), Joris A. Veltman(Radboud University Nijmegen), Frans P.M. Cremers(Radboud University Nijmegen), Hans Scheffer(Radboud University Nijmegen)
Human Mutation
February 14, 2012
Cited by 286Open Access
Full Text

Abstract

Molecular diagnostics for patients with retinitis pigmentosa (RP) has been hampered by extreme genetic and clinical heterogeneity, with 52 causative genes known to date. Here, we developed a comprehensive next-generation sequencing (NGS) approach for the clinical molecular diagnostics of RP. All known inherited retinal disease genes (n = 111) were captured and simultaneously analyzed using NGS in 100 RP patients without a molecular diagnosis. A systematic data analysis pipeline was developed and validated to prioritize and predict the pathogenicity of all genetic variants identified in each patient, which enabled us to reduce the number of potential pathogenic variants from approximately 1,200 to zero to nine per patient. Subsequent segregation analysis and in silico predictions of pathogenicity resulted in a molecular diagnosis in 36 RP patients, comprising 27 recessive, six dominant, and three X-linked cases. Intriguingly, De novo mutations were present in at least three out of 28 isolated cases with causative mutations. This study demonstrates the enormous potential and clinical utility of NGS in molecular diagnosis of genetically heterogeneous diseases such as RP. De novo dominant mutations appear to play a significant role in patients with isolated RP, having major implications for genetic counselling.


Related Papers

No related papers found

Powered by citation graph analysis